(Solid Tumors) Is Tipifarnib Monotherapy Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- June 29, 2020
- Read time: 2 minutes
From May 29–31, 2020, Alan Loh Ho presented at the ASCO 2020 Virtual Meeting the results of "Efficacy and safety of farnesyltransferase inhibitor Tipifarnib monotherapy in patients with HRAS-mutant head and neck squamous cell carcinoma, thyroid cancer, salivary gland tumors, and urothelial carcinoma in the KO-TIP-001 and IST-01 Phase 2 clinical trials."
This Phase 2 clinical trial administered Tipifarnib monotherapy (28-day cycle, Days 1–7 and 15–21, twice-daily Tipifarnib 600–900 mg) to patients with HRAS-mutant head and neck squamous cell carcinoma, thyroid cancer, salivary gland tumors, and urothelial carcinoma. Primary endpoints were objective response rate and 6-month progression-free survival.
In the KO-TIP-001 and IST-01 trials, among evaluable head and neck squamous cell carcinoma patients (N=18): objective response rate was 56% (N=10/18), median progression-free survival was 6.1 months. Among recurrent and metastatic salivary gland tumor patients (N=12): objective response rate was 8% (N=1), median progression-free survival was 7 months. Among urothelial carcinoma patients (N=12): objective response rate was 42% (N=5), median progression-free survival was 5.1 months.
Based on the results of the KO-TIP-001 and IST-01 trials, Alan Loh Ho concluded: In patients with HRAS-mutant head and neck squamous cell carcinoma, thyroid cancer, salivary gland tumors, and urothelial carcinoma, the farnesyltransferase inhibitor Tipifarnib demonstrated anticancer activity.
[Important Note] Medical Supporter's translations of overseas clinical trial data and pharmaceutical information are not intended to encourage participation in clinical trials or use of new drugs. The translated information is for reference only and not intended as medication guidelines. Please discuss with healthcare professionals and refer to the original text below the article for accurate information.
Source: Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations. (2020 ASCO Virtual Scientific Program, Abstract No: 6504)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4